The Development of Novel LTAH Modulators to Selectively Target LTB Generation

Overview

Journal Sci Rep

Specialty Science

Date 2017 Mar 18

PMID 28303931

Citations 19

Authors

Caroline M Low

Samia Akthar

Dhiren F Patel

Stephan Loser

Chi-Tung Wong

Patricia L Jackson

J Edwin Blalock

Stephen A Hare

Clare M Lloyd

Robert J Snelgrove

Affiliations

Soon will be listed here.

Abstract

The pro-inflammatory mediator leukotriene B (LTB) is implicated in the pathologies of an array of diseases and thus represents an attractive therapeutic target. The enzyme leukotriene A hydrolase (LTAH) catalyses the distal step in LTB synthesis and hence inhibitors of this enzyme have been actively pursued. Despite potent LTAH inhibitors entering clinical trials all have failed to show efficacy. We recently identified a secondary anti-inflammatory role for LTAH in degrading the neutrophil chemoattractant Pro-Gly-Pro (PGP) and rationalized that the failure of conventional LTAH inhibitors may be that they inadvertently prevented PGP degradation. We demonstrate that these inhibitors do indeed fail to discriminate between the dual activities of LTAH, and enable PGP accumulation in mice. Accordingly, we have developed novel compounds that potently inhibit LTB generation whilst leaving PGP degradation unperturbed. These novel compounds could represent a safer and superior class of LTAH inhibitors for translation into the clinic.

Citing Articles

Characterization of secretome during sublethal infection of larvae.

Curtis A, Dobes P, Marciniak J, Hurychova J, Hyrsl P, Kavanagh K J Med Microbiol. 2024; 73(6).

PMID: 38836745 PMC: 11261830. DOI: 10.1099/jmm.0.001844.

Using Omics to Identify Novel Therapeutic Targets in Heart Failure.

Lteif C, Huang Y, Guerra L, Gawronski B, Duarte J Circ Genom Precis Med. 2024; 17(3):e004398.

PMID: 38766848 PMC: 11187651. DOI: 10.1161/CIRCGEN.123.004398.

Eicosanoids Signals in SARS-CoV-2 Infection: A Foe or Friend.

Rahman M, Hossain M Mol Biotechnol. 2023; 66(11):3025-3041.

PMID: 37878227 DOI: 10.1007/s12033-023-00919-4.

Lipoxin receptor agonist and inhibition of LTA4 hydrolase prevent tight junction disruption caused by P. aeruginosa filtrate in airway epithelial cells.

Kalsi K, Jackson S, Baines D PLoS One. 2023; 18(7):e0287183.

PMID: 37406028 PMC: 10321624. DOI: 10.1371/journal.pone.0287183.

Modulation of the 5-Lipoxygenase Pathway by Chalcogen-Containing Inhibitors of Leukotriene A Hydrolase.

Teder T, Konig S, Singh R, Samuelsson B, Werz O, Garscha U Int J Mol Sci. 2023; 24(8).

PMID: 37108702 PMC: 10145651. DOI: 10.3390/ijms24087539.

References

Davies D, Mamat B, Magnusson O, Christensen J, Haraldsson M, Mishra R . Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J Med Chem. 2009; 52(15):4694-715. PMC: 2722745. DOI: 10.1021/jm900259h. View

Emsley P, Lohkamp B, Scott W, Cowtan K . Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 4):486-501. PMC: 2852313. DOI: 10.1107/S0907444910007493. View

Whittle B, Varga C, Berko A, Horvath K, Posa A, Riley J . Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. Br J Pharmacol. 2007; 153(5):983-91. PMC: 2267273. DOI: 10.1038/sj.bjp.0707645. View

Evans P . Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr. 2005; 62(Pt 1):72-82. DOI: 10.1107/S0907444905036693. View

Thunnissen M, Nordlund P, Haeggstrom J . Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation. Nat Struct Biol. 2001; 8(2):131-5. DOI: 10.1038/84117. View

Weathington N, van Houwelingen A, Noerager B, Jackson P, Kraneveld A, Galin F . A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med. 2006; 12(3):317-23. DOI: 10.1038/nm1361. View

Jiang X, Zhou L, Wei D, Meng H, Liu Y, Lai L . Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008; 18(24):6549-52. DOI: 10.1016/j.bmcl.2008.10.044. View

Askonas L, Kachur J, Villani-Price D, Liang C, Russell M, Smith W . Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase I: in vitro studies. J Pharmacol Exp Ther. 2002; 300(2):577-82. DOI: 10.1124/jpet.300.2.577. View

Akthar S, Patel D, Beale R, Peiro T, Xu X, Gaggar A . Matrikines are key regulators in modulating the amplitude of lung inflammation in acute pulmonary infection. Nat Commun. 2015; 6:8423. PMC: 4595997. DOI: 10.1038/ncomms9423. View

10.

Funk C . Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001; 294(5548):1871-5. DOI: 10.1126/science.294.5548.1871. View

11.

Barchuk W, Lambert J, Fuhr R, Jiang J, Bertelsen K, Fourie A . Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma. Pulm Pharmacol Ther. 2014; 29(1):15-23. DOI: 10.1016/j.pupt.2014.06.003. View

12.

Winn M, Ballard C, Cowtan K, Dodson E, Emsley P, Evans P . Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 4):235-42. PMC: 3069738. DOI: 10.1107/S0907444910045749. View

13.

Snelgrove R, Jackson P, Hardison M, Noerager B, Kinloch A, Gaggar A . A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science. 2010; 330(6000):90-4. PMC: 3072752. DOI: 10.1126/science.1190594. View

14.

Tager A, Luster A . BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids. 2003; 69(2-3):123-34. DOI: 10.1016/s0952-3278(03)00073-5. View

15.

Griffiths R, Pettipher E, Koch K, Farrell C, Breslow R, Conklyn M . Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci U S A. 1995; 92(2):517-21. PMC: 42772. DOI: 10.1073/pnas.92.2.517. View

16.

Sandanayaka V, Mamat B, Mishra R, Winger J, Krohn M, Zhou L . Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. J Med Chem. 2009; 53(2):573-85. DOI: 10.1021/jm900838g. View

17.

De Oliveira E, Wang K, Kong H, Kim S, Miessau M, Snelgrove R . Effect of the leukotriene A4 hydrolase aminopeptidase augmentor 4-methoxydiphenylmethane in a pre-clinical model of pulmonary emphysema. Bioorg Med Chem Lett. 2011; 21(22):6746-50. PMC: 3209762. DOI: 10.1016/j.bmcl.2011.09.048. View

18.

Setchell K, Faughnan M, Avades T, Zimmer-Nechemias L, Brown N, Wolfe B . Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. Am J Clin Nutr. 2003; 77(2):411-9. DOI: 10.1093/ajcn/77.2.411. View

19.

Wells J, OReilly P, Szul T, Sullivan D, Handley G, Garrett C . An aberrant leukotriene A4 hydrolase-proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014; 190(1):51-61. PMC: 4226028. DOI: 10.1164/rccm.201401-0145OC. View

20.

Murshudov G, Vagin A, Dodson E . Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997; 53(Pt 3):240-55. DOI: 10.1107/S0907444996012255. View